Приверженность пациентов лечению и выбор антигипертензивной терапии: фокус на лерканидипин

1. Acanfora D, Gheorghiade M, Trojano L et al. A randomized, double-blind comparison of lercanidipine 10 and 20 mg in patients with stable effort angina: clinical evaluation of cardiac function by ambulatory ventricular scintigraphic monitoring. Am J Ther 2004; 11: 423–32.
2. Agrawal R, Marx A, Haller H. Efficacy and safety of lercanidipine versus hydrochlorothiazide as add-on to enalapril in diabetic populations with uncontrolled hypertension. J Hypertens 2006; 24: 185–92.
3. Ambrosioni E, Leonetti G, Pessina A et al. Patterns of hypertension management in Italy: results of a pharmacoepidemiological survey on antihypertensive therapy. J Hypertens 2000; 18: 1691–9.
4. Angelico P, Guarnieri N, Leonardi A et al. Vascular-selective effect of leranidipine and other 1,4 dihydropyridines in isolated rabbit tissues. J Pharm Pharmacol 1999; 51: 709–14.
5. Arima S, Ito S, Omata K et al. Role of actions of calcium antagonists on efferent arterioles with special references to glomerular hypertension. Am J Nephrol 1996; 23: 229–44.
6. Bang LM, Chapman TM, Goa KL. Lercanidipine: a review of its effi cacy in the management of hypertension. Drugs 2003; 63: 2449–72.
7. Barrios V, Escobar C, de la Figuera M et al. Tolerability of high doses of lercanidipine versus high doses of other dihydropyridines in daily clinical practice: the TOLERANCE study. Cardiovasc Ther 2008; 26: 2–9.
8. Barrios V, Navarro A, Esteras A et al. Antihypertensive efficacy and tolerability of lercanidipine in daily clinical practice. The ELYPSE study. Efi cacia de Lercanidipino y su Perfi l de Seguridad. Blood Press 2002; 11: 95–100.
9. Basile J. The role of existing and newer calcium channel blockers in the treatment of hypertension. J Clin Hypertens 2004; 6: 621–9.
10. Bloom BS. Continuation of initial antihypertensive medication after 1 year of therapy. Clin Ther 1998; 20: 671–81.
11. Borghi C. Lercanidipine in hypertension. Vasc Health Risk Manag 2005; 1: 173–82.
12. Borghi C, Prandin MG, Dormi A, Ambrosioni E. Study group of the regional Unit of the Italian Society of Hypertension. Improved Tolerability of the dihydropyridine calcium-channel antagonist lercanidipine: the lercanidipine challenge trial. Blood Press Suppl 2003; 1: 14–21.
13. Burnier M, Gasser UE. Effi cacy and tolerability of lercanidipine in patients with hypertension: results of a Phase IV study in general practice. Expert Opin Pharmacother 2007; 8: 2215–23.
14. Burnier M, Santschi V, Favrat B, Brunner HR. Monitoring compliance in resistant hypertension: an important step in patient management. J Hypertens 2003; 21: S37–42.
15. Burnier M, Hess B, Greminger P, Waeber B. Determinants of persistence in hypertensive patients treated with Irbesartan: results of a postmarketing survey. BMC Cardiovasc Disords 2005; 5: 13.
16. Fogari R, Mugellini A, Zoppi A et al. Differential effects of lercanidipine and nifedipine GITS on plasma norepinephrine in chronic treatment of hypertension. Am J Hypertens 2003; 16: 1357–69.
17. Caro JJ, Speckman JL, Salas M et al. Effect of initial drug choice on persistence with antihypertensive therapy: the importance of actual practice data. CMAJ 1999; 160: 41–6.
18. Cleophas TJ, van Ouwekerk BM, van der Meulen J et al. Diabetics with hypertension not controlled with ACE-inhibitors: alternate therapies. Angiology 2001; 52: 469–75.
19. Collins OR, Peto R. Antihypertensive drug therapy: effects on stroke and coronary heart disease. In: Swales JD, (ed). Textbook of Hypertension. Oxford, England: Blackwell Scientifi c Publications. 1994; p. 1156–64.
20. Croog SH, Levine S, Testa MA et al. The effects of antihypertensive therapy on the quality of life. N Engl J Med 1986; 314: 1657–64.
21. Dahlцf B, Severs PS, Poulter NR et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendrofl umethiazide, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering arm (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet 2005; 366: 895–906.
22. DeGiorgio LA, Orlandini F, Malasoma P, Zappa A. Double blind, cross-over study of lercanidipine versus amlodipine in the treatment of mild to moderate essential hypertension. Curr Ther Res 1999; 60: 511–20.
23. Douglas JG, Agodoa L. ACE-inhibition is effective and renoprotective in hypertensive nephrosclerosis: the African American Study of Kidney Disease and Hypertension (AASK) trial. Kidney Int Suppl 2003; 83: S74–6.
24. Grandi AM, Solbiati F, Laurita E et al. Effects of dual blockade of renin-angiotensin system on concentric left ventricular hypertrophy in essential hypertension: a randomized, controlled pilot study. Am J Hypertens 2008; 21: 231–7.
25. Gress TW, Nieto FJ, Shahar E et al. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis risk in communities study. N Engl J Med 2000; 13: 905–12.
26. Guillen VG, Abellan J, Llisterri JL et al. Efficacy and safety of lercanidipine in combination with enalapril in HBP. Preliminary results of ZANYCONTROL study group. Am J Hypertens 2003; 16: 115A.
27. Gupta AK, Dahlof B, Dobson J et al. Determinants of new-onset diabetes among 189,257 hypertensive patients randomized in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm and the relative influence of antihypertensive medication. Diabetes Care 2008; 31: 982–8.
28. Hair PI, Scott LJ, Perry CM. Fixed-dose combination lercanidipine/enalapril. Drugs 2007; 67: 95–106.
29. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988–2000. JAMA 2003; 290: 199 206.
30. Herbette LG, Vecchiarelli M, Sartani A, Leonardi A. Lercanidipine: short plasma half-life, long duration of action and high cholesterol tolerance. Updated molecular models to rationalize its pharmacokinetic properties. Blood Press 1998; Suppl. 2: 10–7.
31. Hollenberg NK. Observations on the safety of lercanidipine: adverse events from placebo-controlled trials. Am J Hypertens 2002; 15: 58A–59A.
32. Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure and the National High Blood.
33. Pressure Education Program Coordination Committee. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Arch Intern Med 1997; 157: 2413–46.
34. Jones JK, Gorkin L, Lian JF et al. Discontinuation of and changes in treatment after start of new courses of antihypertensiv drugs: a study of a United Kingdom population. BMJ 1995; 311: 293–5.
35. Kruse W, Weber E. Dynamics of drug regimen compliance-its assessment by microprocessor-based monitoring. Eur J Clin Pharmacol 1990; 38: 561–5.
36. Loghman-Adham M. Medication Noncompliance in patients with chronic disease: issues in dialysis and renal transplantation. Am J Manag Care 2003; 9: 155–71.
37. Mancia G, De Backer Guy, Dominiczak A et al. Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25: 1105–87.
38. Mason JM, Dickinson HO, Nicolson DJ et al. The diabetogenic potential of thiazide-diuretic and beta blocker combinations in patients with hypertension. J Hypertens 2005; 23: 1779–81.
39. Morb Mortal Wkly Rep (MMWR). Racial/ethnic disparities in prevalence, treatment, and control of hypertension – United States 1999–2002. MMWR 2005; 54: 7–9.
40. Morgan SG, Yan L. Persistence with hypertension treatment among community-dwelling BC seniors. Can J Clin Pharmacol 2004; 11: 267–73.
41. Nedeltchev K, Arnold M, Baumgartner R et al. Vascular risk factors in the Swiss population. J Neurol 2005; 252: 1210–6.
42. Nuesch R, Schroeder K, Dieterle T et al. Relation between insufficient response to antihypertensive treatment and poor compliance with treatment: a prospective case-control study. Br Med J 2001; 323: 142–6.
43. Pedrinelli R, Dell'Omo G, Nuti M et al. Heterogeneous effect of calcium antagonists on leg oedema: a comparison of amlodipine versus lercanidipine in hypertensive patients. J Hypertens 2003; 21: 1969–73.
44. Poncelet P, Ribstein J, Goullard L et al. Effi cacy and acceptability of lercanidipine are not age dependent in patients with essential hypertension: the AGATE study. Ann Cardiol Angeiol 2004; 53: 123–30.
45. Poluzzi E, Strahinja P, Vargiu A et al. Initial treatment of hypertension and adherence to therapy in general practice in Italy. Eur J Clin Pharmacol 2005; 61: 603–9.
46. Puig JG, Calvo C, Luurila O et al. Lercanidipine, enalapril and their combination in the treatment of elderly hypertensive patients: placebo-controlled, randomized, crossover study with four ABPM. J Hum Hypertens 2007; 21: 917–24.
47. Pullar T, Kumar S, Feely M. Compliance in clinical trials. Ann Rheum Dis 1989; 48: 871–5.
48. Robles NR, Ocon J, Gomez CF et al. Lercanidipine in patients with chronic renal failure: the ZAFRA study. Ren Fail 2005; 1: 73–80.
49. Sabbatini M, Leonardi A, Testa R et al. Effect of calcium antagonists on glomerular arterioles in spontaneously hypertensive rats. Hypertension 2000; 35: 775–9.
50. Sasaki T, Maruyama H, Kase Y et al. Antianginal effects of lercanidipine on the vasopressin or metacholine induced anginal models in rats. Biol Pharm Bull 2005; 28: 811–6.
51. Shulman N, Cutter G, Daugherty R et al. Correlates of attendance and compliance in the hypertension detection and follow-up program. Control Clin Trials 1982; 3: 13–27.
52. Simons LA, Ortiz M, Calcino G. Persistence with antihypertensive medication: Australia-wide experience 2004-6. Med J Aust 2008; 188: 224–7.
53. Sironi G, Montagna E, Greto L et al. Haemodynamic effects of lercanidipine in anaesthetized open-chest dogs. Arzneimittelforschung 1996; 46: 256–61.
54. Takabatake T, Ohta H, Sasaki T et al. Renal effects of manidipine hydrochloride: a new calcium antagonist in hypertensive patients. Eur J Clin Pharmacol 1993; 19: 851–6.
55. The ALLHAT offi cers and coordinators for the ALLHAT collaborative research group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2002; 288: 2981–97.
56. Urquhart J, Vrijens B. New findings about patient adherence to prescribed drug dosing regimens: an introduction to pharmionics. Eur J Hospital Pharm Sci 2005; 11: 103–6.
57. Verdecchia P, Reboldi G, Angeli F et al. Angiotensin-converting enzyme inhibitors and calcium channel blockers for coronary heart disease and stroke prevention. Hypertension 2005; 46: 386–92.
58. Veronesi M, Cicero AF, Prandin MG et al. A prospective evaluation of persistence on antihypertensive treatment with different antihypertensive drugs in clinical practice. Vasc Health Risk Manag 2007; 3: 999–1005.
59. Voyaki SM, Staessen JA, Thijs L et al. Follow-up of renal function in treated and untreated older patients with isolated systolic hypertension. J Hypertens 2001; 19: 511–9.
60. Vrijens B, Vincze G, Kristano P et al. Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ 2008; 336: 1114–7.
61. Waeber B, Burnier M, Brunner HR. Compliance with antihypertensive treatment. Clin Exp Hypertens 1999; 21: 973–85.
62. Weir MR, Moser M. Diuretics and beta-blockers: is there a risk for dyslipidemia? Am Heart J 2000; 139: 174–83.
63. World Health Organization: Adherence to long-term therapies. Evidence for action. Geneva: World Health Organization. 2003. URL: http://www.who.int/chronic_conditions/adherencereport/en/index.html.

M.T.Pruijm, M.P.Maillard, M.Burnier